You are here: Industry Insights > Market News > Mindfulness-based therapy may reduce stress in obese patients

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Mindfulness-based therapy may reduce stress in obese patients

europeanpharmaceuticalreviewJuly 10, 2017

Tag: obese patients , Mindfulness-based therapy

Favorites

In a randomised clinical trial of women who were overweight or obese, mindfulness-based stress reduction (MBSR) increased mindfulness and decreased stress compared with health education.

In addition, fasting blood sugar levels decreased within the MBSR group, but not within the health education group.

Study specifics

In the study, 86 women were randomized to 8 weeks of MBSR or health education, and they were followed for 16 weeks. While MBSR significantly reduced stress and had beneficial effects on blood sugar levels, there were no significant changes in blood pressure, weight, or insulin resistance.

"Our study suggests that MBSR lowers perceived stress and blood sugar in women with overweight or obesity. This research has wider implications regarding the potential role of MBSR in the prevention and treatment of diabetes in patients with obesity," said Dr Nazia Raja-Khan, lead author of the Obesity study.

Previous:Embarrassing Two Different Worlds in Consistency Evaluation: Some about to Win, in the Wrong Track

Next:Vitamin D may improve sunburn, says new trial

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Mindfulness-based therapy may reduce stress in obese patients | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Mindfulness-based therapy may reduce stress in obese patients

Study specifics

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Mindfulness-based therapy may reduce stress in obese patients

Study specifics

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>